What's Happening?
Codexis, Inc., a leader in enzymatic solutions for therapeutics manufacturing, will present new data on its ECO Synthesis® Manufacturing Platform at the TIDES USA conference in Boston. The company will showcase advances in RNA manufacturing, focusing
on controlling phosphorothioate stereochemistry and improving ligation efficiency. These innovations are crucial as RNAi therapies expand into larger indications, requiring scalable and high-quality manufacturing processes. Codexis will also host a panel discussion on stereochemistry in RNAi manufacturing, featuring industry experts.
Why It's Important?
Codexis' advancements in RNA manufacturing are significant for the biopharmaceutical industry, particularly as RNAi therapies gain traction for treating various diseases. The company's innovations could lead to more efficient and sustainable manufacturing processes, reducing costs and improving product quality. This is vital for the scalability of RNAi therapies, which hold promise for silencing disease-causing genes. The panel discussion at TIDES USA will provide a platform for industry leaders to explore the implications of these advancements, potentially influencing future manufacturing standards and practices.
What's Next?
Following the TIDES USA conference, Codexis will continue to refine its RNA manufacturing processes and engage with regulatory bodies to ensure compliance and quality. The company's focus on sustainability and efficiency could set new benchmarks in the industry, encouraging other manufacturers to adopt similar practices. As RNAi therapies continue to evolve, Codexis' role in providing scalable solutions will be crucial in meeting the growing demand for these innovative treatments. The outcomes of the conference and subsequent developments could shape the future of RNA therapeutics manufacturing.
